SUNRIDGE MEDICAL • INTEGRATIVE ONCOLOGY
Broccoli sprouts, standardized extracts and research compounds produce different exposures. A physician can review the product, diet, medications and treatment context.
Share your diagnosis, current treatment and the sulforaphane source or product you are considering.
Sulforaphane and cancer research has become especially compelling because this broccoli-derived isothiocyanate has been studied not only for effects on ordinary tumor cells, but also for effects on cancer stem cells, apoptosis, epigenetic regulation, drug resistance and metastatic signaling.
Sulforaphane (SFN) is produced from the glucosinolate glucoraphanin found in cruciferous vegetables, particularly broccoli sprouts. The National Cancer Institute describes sulforaphane as an agent with anticarcinogenic properties and identifies broccoli sprouts as a particularly rich source.1
At Sunridge Medical in Scottsdale, Arizona, sulforaphane or standardized broccoli-sprout preparations may be considered as part of a physician-directed integrative cancer treatment strategy when appropriate for the individual patient.
This page examines the research in depth, including triple-negative breast cancer, breast cancer stem cells, lung cancer, cholangiocarcinoma, pancreatic cancer, prostate cancer, glioblastoma, melanoma and colorectal cancer.
Broccoli sprouts are among the richest dietary sources of glucoraphanin, the precursor used to form sulforaphane.
BROCCOLI-DERIVED ISOTHIOCYANATE
Sulforaphane is an isothiocyanate generated when glucoraphanin comes into contact with the enzyme myrosinase. This occurs when broccoli sprouts or other cruciferous vegetables are disrupted and the precursor is converted into the active compound.
The National Cancer Institute identifies sulforaphane as one of the most frequently examined biologically active compounds derived from cruciferous vegetables.2
Research interest extends well beyond its food origin. Sulforaphane has been investigated for effects on detoxification enzymes, redox signaling, histone deacetylases, inflammatory pathways, apoptosis, cell-cycle control and tumor-initiating stem-like cells.
GLUCORAPHANIN • MYROSINASE • BIOAVAILABILITY
A broccoli sprout supplement does not necessarily deliver the same sulforaphane exposure as preformed sulforaphane.
Glucoraphanin is the precursor. Myrosinase is the enzyme that converts glucoraphanin into sulforaphane. Formulation therefore matters.
Human pharmacokinetic research has shown that preformed sulforaphane is absorbed and eliminated much more consistently than glucoraphanin preparations that rely on conversion inside the body.3
For an oncology program, the exact preparation matters because biological exposure may differ substantially even when two products both use the words “broccoli sprout extract.”
NRF2 • CELLULAR DEFENSE
One of sulforaphane’s best-characterized effects is activation of Nrf2, a transcription factor involved in cellular defense and detoxification.
NCI describes broccoli sprout and broccoli seed extracts as activating Nrf2 and antioxidant-response elements, leading to expression of cytoprotective and phase II detoxification enzymes.4
This biology is particularly relevant to cancer prevention and carcinogen handling. It also illustrates why sulforaphane can have different roles depending upon whether the goal is protecting normal tissue from carcinogenic stress or directly influencing an established tumor.
EPIGENETIC REGULATION
Sulforaphane is also studied as a naturally occurring histone deacetylase (HDAC) inhibitor.
HDACs help regulate how tightly DNA is packaged and which genes are available for transcription. Abnormal HDAC activity is common in cancer and can contribute to silencing of tumor-suppressor pathways.
Experimental and translational work has shown that sulforaphane can influence histone acetylation, DNA methylation and other epigenetic processes. This epigenetic activity is one reason sulforaphane has been studied in breast, prostate, colorectal and cholangiocarcinoma models.
PROGRAMMED CELL DEATH
Apoptosis is the controlled process by which damaged or abnormal cells are eliminated. Cancer cells frequently develop resistance to apoptosis, allowing them to survive despite DNA damage, metabolic stress or anticancer therapy.
Sulforaphane has been studied for effects on both intrinsic mitochondrial and extrinsic death-receptor pathways. Experimental studies have reported changes in BCL-2 family proteins, XIAP, caspase activation, mitochondrial signaling and TRAIL sensitivity.
In pancreatic cancer stem-cell research, sulforaphane downregulated the anti-apoptotic proteins BCL-2 and XIAP while reducing Sonic Hedgehog signaling and stemness markers.5
In advanced prostate cancer stem-like cells, sulforaphane combined with TRAIL produced synergistic elimination of apoptosis-resistant stem-like populations.6
Sulforaphane research includes tumor-initiating cancer stem cells, self-renewal pathways and treatment resistance.
CANCER STEM CELLS
Cancers are composed of biologically different cell populations. A relatively small subgroup can display cancer stem cell (CSC) properties: self-renewal, tumor initiation, resistance to therapy and the ability to regenerate a heterogeneous tumor.
These stem-like populations are important because a therapy can substantially shrink a tumor while leaving behind cells capable of initiating recurrence.
Sulforaphane is unusual among natural compounds because cancer stem cells have been a central focus of its experimental research rather than an afterthought.
Published studies have examined breast, triple-negative breast, lung, pancreatic, prostate, glioblastoma and melanoma stem-like cells.
BREAST CANCER STEM CELLS
A landmark 2010 study tested sulforaphane against breast cancer stem cells using ALDH-positive populations, mammosphere assays and a xenograft model.
Sulforaphane reduced the ALDH-positive breast-cancer cell population, markedly decreased mammosphere formation and downregulated the Wnt/β-catenin self-renewal pathway.7
When tumor cells from treated animals were reimplanted into secondary mice, tumor-initiating capacity was reduced. This was important because it suggested an effect on the stem-like population rather than only on bulk tumor cells.
TRIPLE-NEGATIVE BREAST CANCER
Triple-negative breast cancer (TNBC) lacks estrogen receptor, progesterone receptor and HER2 expression and has been a major focus of sulforaphane cancer-stem-cell research.
A 2019 TNBC study found that sulforaphane inhibited cell proliferation and mammosphere formation and reduced expression of stem-cell-associated markers including Nanog, ALDH1A1, Wnt3 and Notch4. The investigators linked part of the effect to suppression of Cripto-related signaling.8
Another TNBC study examined paclitaxel and docetaxel together with sulforaphane. Taxanes increased IL-6 and enriched ALDH-positive cancer stem cells, while sulforaphane reduced NF-κB signaling, reversed ALDH-positive enrichment and decreased primary and secondary mammosphere formation.9
In the animal model used in that study, docetaxel plus sulforaphane reduced primary tumor volume and secondary tumor formation more than either treatment alone.9
TNBC • CHEMORESISTANCE
Additional TNBC research has examined sulforaphane with cisplatin.
A 2021 study reported that the sulforaphane-cisplatin combination reduced stemness and metastatic characteristics in TNBC cells through effects involving sirtuins and the epithelial-mesenchymal transition cascade.10
These findings are preclinical. Their importance is mechanistic: they suggest that sulforaphane may influence cellular populations and signaling pathways associated with treatment resistance and recurrence.
LUNG CANCER STEM CELLS
Non-small cell lung cancer has also been studied from a cancer-stem-cell perspective.
A 2017 study found that sulforaphane inhibited stem-like properties and increased cisplatin sensitivity through miR-214-mediated downregulation of c-MYC in NSCLC models.11
A separate 2021 study reported that sulforaphane inhibited both lung-cancer-cell proliferation and lung cancer stem-cell self-renewal through modulation of Sonic Hedgehog signaling and stem-cell regulatory pathways.12
This makes sulforaphane a logical internal research link from Sunridge’s lung-cancer page, particularly from sections discussing natural compounds, stemness and treatment resistance.
PANCREATIC CANCER STEM CELLS
Pancreatic cancer is one of the tumor types in which sulforaphane has been repeatedly studied against stem-like populations.
Experimental work showed that sulforaphane inhibited Sonic Hedgehog signaling, reduced Nanog and Oct-4, decreased angiogenic and epithelial-mesenchymal-transition markers, downregulated BCL-2 and XIAP, and induced apoptosis in pancreatic cancer stem-cell models.5
Another study found that sulforaphane increased drug-mediated cytotoxicity toward pancreatic and prostate cancer stem-like cells.13
Research has also examined combinations of sulforaphane with quercetin and catechins in advanced pancreatic cancer models, which provides a useful internal connection to Sunridge’s quercetin and EGCG research pages.14
GLIOBLASTOMA STEM-LIKE CELLS
Glioblastoma contains therapy-resistant stem-like populations that are strongly implicated in recurrence.
A 2017 study reported that sulforaphane suppressed growth of glioblastoma cells, glioblastoma stem cell-like spheroids and tumor xenografts through multiple cellular pathways.15
This is preclinical research, but it adds glioblastoma to the growing list of cancers in which sulforaphane has been evaluated specifically against stem-like tumor populations.
MELANOMA STEM CELLS
Melanoma research has identified the epigenetic protein EZH2 as an important survival factor in aggressive melanoma stem-like cells.
A 2016 study found that sulforaphane suppressed melanoma cancer stem-cell spheroid survival, migration and invasion and reduced tumor formation in mice in association with reduced EZH2 activity and increased apoptosis.16
This study is particularly interesting because it connects sulforaphane’s cancer-stem-cell effects with its broader epigenetic activity.
INTRAHEPATIC CHOLANGIOCARCINOMA
Cholangiocarcinoma deserves a dedicated section because there is newer disease-specific research involving sulforaphane and gemcitabine.
A 2023 study evaluated sulforaphane with gemcitabine in human intrahepatic cholangiocarcinoma (iCCA) models. The investigators reported that sulforaphane potentiated gemcitabine-mediated anticancer effects and linked the combination to inhibition of HDAC activity.17
The study included human iCCA cells and an experimental xenograft model. This provides a direct research connection between sulforaphane, epigenetic regulation and a chemotherapy commonly used in biliary tract cancer.
This is the cholangiocarcinoma study Sunridge should link to from the botanical-medicine or metabolic/epigenetic section of the cholangiocarcinoma page.
PROSTATE CANCER
Prostate cancer has one of the more developed human sulforaphane research programs.
Preclinical work has investigated androgen-receptor signaling, apoptosis, autophagy, HDAC inhibition, prostate cancer stem-like cells and metastatic biology.
In advanced prostate cancer stem-like cells, sulforaphane has also been studied together with TRAIL, where the combination produced synergistic elimination of stem-like cells that were resistant to apoptosis.6
Unlike many natural compounds, sulforaphane has also advanced into several human prostate studies.
HUMAN PROSTATE RESEARCH
In a phase II study, 20 men with recurrent prostate cancer received sulforaphane-rich broccoli-sprout extract for up to 20 weeks. The trial’s primary endpoint—PSA declines of at least 50%—was not achieved in most patients; however, seven men had smaller PSA declines and median PSA doubling time increased from 6.1 months before treatment to 9.6 months during treatment.18
A separate randomized placebo-controlled multicenter trial in 78 men with biochemical recurrence after prostatectomy reported a slower rise in PSA during six months of stabilized sulforaphane treatment, although the study’s prespecified primary endpoint was not met.19
A randomized trial in men presenting for prostate biopsy also evaluated sulforaphane bioavailability and prostate-tissue effects.20
These human studies do not establish sulforaphane as a prostate-cancer treatment, but they make prostate cancer one of the strongest clinical-research areas for this compound.
BREAST TISSUE • HUMAN TRANSLATION
Human breast research has also demonstrated that metabolites derived from broccoli-sprout preparations can reach breast tissue.
Clinical translational work evaluated sulforaphane bioavailability and tissue biomarkers in women undergoing breast procedures and found measurable exposure, although short-term supplementation did not produce broad changes in all tumor biomarkers studied.21
Earlier work also demonstrated pharmacodynamic effects of orally administered sulforaphane in mammary tissue and helped establish that orally delivered broccoli-derived compounds can reach the breast.22
COLORECTAL CANCER
Colorectal-cancer research has examined sulforaphane in relation to apoptosis, HDAC inhibition, Wnt/β-catenin biology, oxidative signaling, cell-cycle arrest and cancer stem cells.
A 2024 review of organosulfur compounds in colorectal-cancer research summarized mechanisms including apoptosis, histone-deacetylase inhibition, β-catenin signaling, angiogenesis, metastatic pathways and inhibition of cancer stem cells.23
Much of this evidence remains preclinical, but colorectal cancer is a major mechanistic research area for sulforaphane and other cruciferous-vegetable isothiocyanates.
COMBINATION STRATEGIES
Some of the most interesting sulforaphane research involves combinations rather than sulforaphane alone.
Experimental studies have examined combinations with taxanes in TNBC, cisplatin in TNBC and lung cancer, gemcitabine in cholangiocarcinoma, TRAIL in pancreatic and prostate cancer, and doxorubicin in breast-cancer models.
In an orthotopic breast-cancer model, sulforaphane enhanced the antitumor effects of doxorubicin while protecting cardiac cells in the experimental system.24
These results do not mean sulforaphane should automatically be combined with chemotherapy. They show why treatment timing, drug interactions and tumor biology deserve physician-level consideration.
A DISTINCTIVE MECHANISTIC PROFILE
Sulforaphane is compelling because several research themes converge:
This is why sulforaphane and cancer deserves a dedicated Sunridge research page rather than a few sentences buried within a general supplement section.
BIOAVAILABILITY • FORMULATION
The amount of sulforaphane generated from a broccoli-derived product can vary dramatically.
Products containing preformed sulforaphane differ from glucoraphanin products. Myrosinase activity, processing, storage and gastrointestinal conversion can all influence exposure.
Human studies demonstrate much greater and more predictable bioavailability from sulforaphane-containing preparations than from glucoraphanin alone.3
For physician-directed integrative oncology, this means product selection cannot be based only on the milligrams printed on a broccoli-sprout label.
PHYSICIAN-DIRECTED USE
At Sunridge Medical, sulforaphane may be considered as part of a larger integrative cancer strategy.
Clinical considerations can include:
The goal is to use research-driven natural compounds deliberately rather than simply adding a large number of supplements to a cancer regimen.
FREQUENTLY ASKED QUESTIONS
Sulforaphane is an isothiocyanate produced from glucoraphanin in cruciferous vegetables. Broccoli sprouts are particularly rich in its precursor.
Research has examined sulforaphane for effects on Nrf2, HDAC activity, apoptosis, NF-κB, Wnt/β-catenin, Sonic Hedgehog, c-MYC, cancer stem cells, angiogenesis and treatment resistance.
Cancer stem cells are tumor-cell populations with self-renewal and tumor-initiating properties. They are studied because they may contribute to treatment resistance, recurrence and metastasis.
Preclinical studies have reported reductions in ALDH-positive breast cancer stem-cell populations, mammosphere formation and Wnt/β-catenin self-renewal signaling after sulforaphane exposure.
Yes. TNBC studies have evaluated sulforaphane against stem-like cells and in combination with taxanes or cisplatin in preclinical models.
Yes. NSCLC studies have examined sulforaphane in relation to c-MYC, miR-214, cisplatin resistance and lung cancer stem-cell self-renewal.
Yes. A 2023 study evaluated sulforaphane with gemcitabine in intrahepatic cholangiocarcinoma models and reported enhanced anticancer effects associated with HDAC inhibition.
Yes. Human studies include prostate-cancer trials and translational breast-tissue studies. The human evidence is still much smaller than the laboratory and animal evidence.
Sulforaphane has extensive preclinical research and some human clinical research, but it is not established as a stand-alone treatment for cancer.
Sulforaphane or standardized broccoli-derived preparations may be considered within individualized physician-directed integrative oncology programs when clinically appropriate.
BECOME A PATIENT
Sulforaphane is one of the most extensively studied cruciferous-vegetable compounds in cancer biology, with research spanning epigenetics, apoptosis, cancer stem cells and treatment resistance.
Speak with our Patient Care Team about your diagnosis, previous treatment and current goals.
RESEARCH
Browse 15 source-linked studies with the full title, publication year, research focus and a concise finding. Select any linked cancer type to move directly to its corresponding Sunridge page.
Here, we unravel the effects of sulforaphane (SFN), an isothiocyanate in cruciferous vegetables, on the assembly of pseudopodia and BC metastasis, and its molecular mechanism in the process.
This study aimed to elucidate the role and underlying molecular mechanisms of SFN in regulating GBM progression, particularly through the endoplasmic reticulum stress (ERS) and unfolded protein response (UPR) pathways.
Sulforaphane (SFN) is a promising phytochemical with a wide range of antitumor activities.
Here, we showed that SFN, including its two isomers of R-SFN and S-SFN, significantly inhibited TGF-β1-induced migration and invasion in breast cancer cells.
The study reports retraction Note: Sulforaphane induces S-phase arrest and apoptosis via p53-dependent manner in gastric cancer cells.
Subsequently, using gastric cancer data from TCGA and 11 pairs of clinical samples from gastric and paracancerous tissues, we found that PSMB8-AS1 was upregulated in gastric cancer, and high expression of PSMB8-AS1 was associated with low survival of patients with gastric cancer.
Sulforaphane (SFN), a natural isothiocyanate, exhibits antitumor activity; however, its molecular mechanisms of action in GC remain unclear.
Compared with vehicle, sulforaphane significantly reduced the incidence and size of 4NQO-induced tongue tumors in mice.
Cell proliferation and HDAC activity (44% in 24 h and 40% in 48 h) were significantly inhibited (p < 0.01).
Sulforaphane has been demonstrated to exert numerous biological effects, such as neuroprotective, anti-inflammatory, and anticancer effects.
Sulforaphane-cysteine (SFN-Cys) is a naturally-occurring form of plant-derived isothiocyanate metabolites that displays several tumor-suppressive properties.
The presence of sulforaphane (SFN) in cruciferous vegetables has been found to possess anti-cancer effects in gastric and colon cancers.
Sulforaphane (SFN), a bioactive compound derived from cruciferous vegetables, exhibits anti-cancer properties, though its role in pancreatic cancer is poorly understood.
Furthermore, the verification experiments showed that the activators of Wnt/β-catenin (LiCl) and hedgehog (purmorphamine) attenuated the effects of SFN on PCSCs, including the expression of stem cell markers, cell proliferation and apoptosis.
Sulforaphane (SFN), an isothiocyanate compound, has been shown to exert inhibitory effects on a variety of cancers.
No studies match those filters. Clear a filter or try a broader term.
14200 N Northsight Blvd #160
Scottsdale, Arizona 85260
Monday–Friday: 9:00 AM–5:00 PM
Saturday: 9:00 AM–12:00 PM
Tell us what you are facing. There is no charge to speak with our Patient Care Team, understand how Sunridge works and determine whether a physician consultation may be an appropriate next step.
This introductory call is not a medical consultation and does not establish a physician-patient relationship.
